ClinicalTrials.gg
Status unknownNCT03433248RACELINESUpdated Jan 14, 2022

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES

A Phase 4 interventional study of EMPA/LINA 10/5 mg QD (n=22) and LINA/EMPA 5/10 mg QD (N=22) in Type2 Diabetes, sponsored by M.H.H. Kramer. Status unknown at 1 site in Netherlands. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-14.

Sponsored by M.H.H. Kramer · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
73rd of 130
66 · median 79
Started
2017
with 13 others
Phase 4
50 of 130
11 open now
Registered
59th of 130
by date

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 73rd largest by enrollment, is one of 14 that started in 2017, is one of 50 in phase 4, and was the 59th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated T2DM patients.

Read the detailed description

Sodium-glucose linked transporters (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors are relatively novel glucose-lowering drugs for the treatment of T2DM. These agents seem to exert pleiotropic actions 'beyond glucose control'. SGLT-2 inhibitors decrease proximal sodium reabsorption and decrease glomerular pressure and albuminuria in rodents and type 1 diabetes patients. In addition, SGLT-2 inhibitors reduce, blood pressure and body weight. In rodents, SGLT-2 inhibitors also improved histopathological abnormalities associated with DKD. DPP-4 inhibitors are considered weight neutral, improve lipid profiles and slight reductions in blood pressure have been reported. To date, the potential renoprotective effects and mechanisms of SGLT-2 inhibitors and combination therapy with SGLT-2 inhibitors have not been sufficiently detailed in human type 2 diabetes. The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with an SGLT-2 inhibitor and a DPP-4 inhibitor on renal physiology and biomarkers in metformin-treated T2DM patients.

66 patients with type 2 diabetes will undergo a 16-week intervention period with 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy or 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy or 8-week gliclazide (SU derivative), followed by 8-week gliclazide intensification therapy in order to assess changes in the outcome parameters.

03

Conditions studied

  • Type2 Diabetes

Keywords

  • Type 2 diabetes mellitus
  • Diabetic kidney disease
  • Diabetic nephropathy
  • Renoprotection
  • SGLT2 inhibitor
  • Empagliflozin
  • DPP-4 inhibitor
  • Linagliptin
  • SU derivative
  • Gliclazide
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian*
  • Both genders (females must be ; no menses >1 year; in case of doubt, Follicle-Stimulating Hormone (FSH) will be determined with cut-off defined as >31 U/L)
  • Age: 35 - 75 years
  • : >25 kg/m2
  • : 7.0 - 9.5% Diabetes Control and Complications Trial (DCCT) or 53 - 80 mmol/mol International Federation of Clinical Chemistry (IFCC)
  • Treatment with a stable dose of oral antihyperglycemic agents for at least 3 months prior to inclusion
  • Metformin monotherapy
  • Combination of metformin and low-dose SU derivative**
  • Hypertension should be controlled, i.e. ≤140/90 mmHg, and treated with an ACE-I or ARB (unless prevented by adverse effect) for at least 3 months.
  • Albuminuria should be treated with a RAAS-interfering agent (ACE-I or ARB) for at least 3 months.
  • Written

    • In order to increase homogeneity ** In order to accelerate inclusion, patients using combined metformin/SU derivative will be considered. In these patients, a 12 week of the SU derivative will be observed, only when combined use has led to a HbA1c \<8% at screening. Subsequently, patients will be eligible to enter the study, now using metformin monotherapy, provided that HbA1c still meets inclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Estimated \<45 mL/min/1.73m2 (determined by the Modification of Diet in Renal Disease (MDRD) study equation)
  • level \< 7.0 mmol/L
  • Current urinary tract infection and active nephritis
  • History of unstable or rapidly progressing renal disease
  • Macroalbuminuria; defined as ACR of >300 mg/g.
  • Current/chronic use of the following medication: thiazolidinediones, sulfonylurea derivatives, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitor, oral , immune suppressants, antimicrobial agents, chemotherapeutics, antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MOAIs).
  • Patients on diuretics will only be excluded when these drugs cannot be stopped 3 months prior randomization and for the duration of the study.
  • Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports injury, head-ache or back ache). However, no such drugs can be taken within a time-frame of 2 weeks prior to renal-testing
  • Pregnancy
  • History of or actual severe mental disease
  • History of or actual severe somatic disease (e.g. systemic disease)
  • History of or actual (except basal cell carcinoma)
  • History of or actual pancreatic disease
  • (Unstable) thyroid disease
  • Severe hepatic insufficiency and/or significant abnormal liver function defined as (AST) >3x (ULN)
  • Recent (\<6 months) history of cardiovascular disease, including

    • Acute coronary syndrome
    • Stroke or transient ischemic neurologic disorder or chronic heart failure ( grade II-IV)
  • Complaints compatible with or established neurogenic bladder and/or incomplete bladder emptying (as determined by ultrasonic bladder scan)
  • Substance abuse (alcohol: defined as >3 units alcohol/day)
  • History of diabetic ketoacidosis (DKA) requiring medical intervention (e.g., emergency room visit and/or hospitalization) within 1 month prior to the Screening visit.
  • Recent blood donation (\< 6 months)
  • Allergy to any of the agents used in the study
  • Inability to understand the protocol and/or give
  • Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    EMPA/LINA 10/5 mg QD (n=22)

    8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)

    Drug: EMPA/LINA 10/5 mg QD (n=22) · Drug: LINA/EMPA 5/10 mg QD (N=22)

  • Experimental
    LINA/EMPA 5/10 mg QD (N=22)

    8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)

    Drug: EMPA/LINA 10/5 mg QD (n=22) · Drug: LINA/EMPA 5/10 mg QD (N=22)

  • Active comparator
    Gliclazide 30 mg QD/BID (N=22)

    8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)

    Drug: Gliclazide 30 mg QD/BID (N=22)

Interventions

  • DrugEMPA/LINA 10/5 mg QD (n=22)

    Drug page: Empagliflozin

    Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg

    Also known as: Jardiance, Tradjenta

  • DrugLINA/EMPA 5/10 mg QD (N=22)

    Drug page: Linagliptin

    Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg

    Also known as: Tradjenta, Jardiance

  • DrugGliclazide 30 mg QD/BID (N=22)

    Drug page: Gliclazide

    Once daily or twice daily treatment with oral glicazide MR 30mg

    Also known as: Gliclazide Sandoz

06

What researchers measure

Primary outcomes

  1. GFR

    Changes from baseline following 16-week treatment on renal hemodynamics in both the fasting and postprandial state, measured as GFR (determined by the inulin-clearance technique)

    Time frame: 16 weeks

  2. GFR

    Changes from baseline following 8-week treatment on renal hemodynamics in both the fasting and postprandial state, measured as GFR (determined by the inulin-clearance technique)

    Time frame: 8 weeks

Secondary outcomes

  1. Renal tubular function

    24-hour urine sodium-, potassium-, chloride-, calcium-, magnesium-, phosphate-, uric acid-, bicarbonate-, ammonium-, urea- and glucose excretion, urine osmolality and urinary pH

    Time frame: 16 weeks

  2. Renal tubular function

    24-hour urine sodium-, potassium-, chloride-, calcium-, magnesium-, phosphate-, uric acid-, bicarbonate-, ammonium-, urea- and glucose excretion, urine osmolality and urinary pH

    Time frame: 8 weeks

  3. Renal Damage

    24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)

    Time frame: 16 weeks

  4. Renal Damage

    24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)

    Time frame: 10 weeks

  5. Renal Damage

    24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)

    Time frame: 8 weeks

  6. Renal Damage

    24-hour urinary albumin excretion, albumin/creatinine ratio (UCR)

    Time frame: 2 weeks

  7. Heart Rate (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 16 weeks

  8. Heart Rate (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 10 weeks

  9. Heart Rate (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 8 weeks

  10. Heart Rate (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 2 weeks

  11. Blood Pressure (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 16 weeks

  12. Blood Pressure (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 10 weeks

  13. Blood Pressure (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 8 weeks

  14. Blood Pressure (Dinamap®)

    Measured using an automated oscillometric blood pressure device (Dinamap®)

    Time frame: 2 weeks

Other outcomes

  1. Body anthropometrics: Body mass index

    Body mass index

    Time frame: 16 weeks

  2. Body anthropometrics: Body mass index

    Body mass index

    Time frame: 8 weeks

  3. Body anthropometrics: Body weight

    Body weight

    Time frame: 16 weeks

  4. Body anthropometrics: Body weight

    Body weight

    Time frame: 8 weeks

  5. Body anthropometrics: Height

    Height

    Time frame: 16 weeks

  6. Body anthropometrics: Height

    Height

    Time frame: 8 weeks

  7. Body anthropometrics: Waist circumference

    Waist circumference

    Time frame: 16 weeks

  8. Body anthropometrics: Waist circumference

    Waist circumference

    Time frame: 8 weeks

  9. Body anthropometrics: Hip circumference

    Hip circumference

    Time frame: 16 weeks

  10. Body anthropometrics: Hip circumference

    Hip circumference

    Time frame: 8 weeks

  11. Body fat content

    Body fat content by bioimpedance analysis

    Time frame: 16 weeks

  12. Body fat content

    Body fat content by bioimpedance analysis

    Time frame: 8 weeks

  13. Blood pressure (NexFin®)

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  14. Blood pressure (NexFin®)

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  15. Heart Rate (NexFin®)

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  16. Heart Rate (NexFin®)

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  17. Stroke Volume

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  18. Stroke Volume

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  19. Cardiac output

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  20. Cardiac output

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  21. Cardiac index

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  22. Cardiac index

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  23. Total systemic vascular resistance

    Continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  24. Total systemic vascular resistance

    Continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  25. Cardiac autonomic nervous system function

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  26. Cardiac autonomic nervous system function

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  27. Microvascular function

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 16 weeks

  28. Microvascular function

    Measured by continuous beat-to-beat hemodynamic monitor (NexFin®)

    Time frame: 8 weeks

  29. Arterial stiffness

    Assessed by radial artery applanation tonometry (SphygmoCor®)

    Time frame: 16 weeks

  30. Arterial stiffness

    Assessed by radial artery applanation tonometry (SphygmoCor®)

    Time frame: 8 weeks

  31. Insulin sensitivity (M-value)

    Derived from the glucose infusion rate during the euglycemic clamp (M-value)

    Time frame: 16 weeks

  32. Insulin sensitivity (M-value)

    Derived from the glucose infusion rate during the euglycemic clamp (M-value)

    Time frame: 8 weeks

  33. Insulin sensitivity (OGIS)

    Meal tolerance test (OGIS)

    Time frame: 16 weeks

  34. Insulin sensitivity (OGIS)

    Meal tolerance test (OGIS)

    Time frame: 8 weeks

  35. Insulin sensitivity (Matsuda index)

    Meal tolerance test (Matsuda index)

    Time frame: 16 weeks

  36. Insulin sensitivity (Matsuda index)

    Meal tolerance test (Matsuda index)

    Time frame: 8 weeks

  37. Beta-cell function (insulinogenic index)

    Meal tolerance test (insulinogenic index)

    Time frame: 16 weeks

  38. Beta-cell function (insulinogenic index)

    Meal tolerance test (insulinogenic index)

    Time frame: 8 weeks

  39. Beta-cell function (HOMA-B)

    HOMA-B

    Time frame: 16 weeks

  40. Beta-cell function (HOMA-B)

    HOMA-B

    Time frame: 8 weeks

  41. Beta-cell function (ratio of postprandial glucose and C-peptide)

    Meal tolerance test (ratio of postprandial glucose and C-peptide)

    Time frame: 16 weeks

  42. Beta-cell function (ratio of postprandial glucose and C-peptide)

    Meal tolerance test (ratio of postprandial glucose and C-peptide)

    Time frame: 8 weeks

  43. Lipid spectrum

    (triglycerides (TG), total-cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)

    Time frame: 16 weeks

  44. Lipid spectrum

    (triglycerides (TG), total-cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)

    Time frame: 8 weeks

  45. DPP-4

    DPP-4 activity

    Time frame: 16 weeks

  46. DPP-4

    DPP-4 activity

    Time frame: 8 weeks

  47. ACE

    ACE activity

    Time frame: 16 weeks

  48. ACE

    ACE activity

    Time frame: 8 weeks

  49. HbA1c (%)

    HbA1c (%)

    Time frame: 16 weeks

  50. HbA1c (%)

    HbA1c (%)

    Time frame: 8 weeks

  51. Fasting plasma glucose (mmol/L)

    Fasting plasma glucose (mmol/L)

    Time frame: 16 weeks

  52. Fasting plasma glucose (mmol/L)

    Fasting plasma glucose (mmol/L)

    Time frame: 8 weeks

  53. Postprandial plasma glucose (mmol/L)

    Postprandial plasma glucose (mmol/L)

    Time frame: 16 weeks

  54. Postprandial plasma glucose (mmol/L)

    Postprandial plasma glucose (mmol/L)

    Time frame: 8 weeks

  55. Free Fatty Acids (FFA) (mmol/L)

    Free Fatty Acids (FFA) (mmol/L)

    Time frame: 16 weeks

  56. Free Fatty Acids (FFA) (mmol/L)

    Free Fatty Acids (FFA) (mmol/L)

    Time frame: 8 weeks

  57. Insulin (mg/L)

    Insulin (mg/L)

    Time frame: 16 weeks

  58. Insulin (mg/L)

    Insulin (mg/L)

    Time frame: 8 weeks

  59. Glucagon (mg/L)

    Glucagon (mg/L)

    Time frame: 16 weeks

  60. Glucagon (mg/L)

    Glucagon (mg/L)

    Time frame: 8 weeks

07

Study locations

1 site
  • VU University Medical Center
    Amsterdam, Noord-Holland 1081HV, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2021, 42 months.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 42 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2017
First posted
Feb 14, 2018
StartActual
Nov 9, 2017
Primary completionActual
Jun 1, 2021
CompletionEst.
Sep 1, 2022
Last update
Jan 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03433248
Lead sponsor
M.H.H. Kramer
Responsible party
M.H.H. Kramer (Head of the Internal Medicine department, Amsterdam UMC, location VUmc) — Sponsor-investigator
First posted
Feb 14, 2018
Start date
Nov 9, 2017
Primary completion
Jun 1, 2021
Completion
Sep 1, 2022 (estimated)
Last update
Jan 14, 2022

Study contacts

Mark HH Kramer, MD PhD
principal investigator · Amsterdam UMC, location VUmc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Linagliptin · Gliclazide

Start the discussion